FRESENIUS MEDICAL CARE-ADR (FMS:NYSE)
$23.03 0.66 (2.9504%)
Analysed FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) News Sources
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
27-05-2026
yahoo.com
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
28-05-2026
yahoo.com
Assessing Fresenius Medical Care (XTRA:FME) Valuation After Recent Share Price Weakness
29-05-2026
yahoo.com
Fresenius (FMS) Q1 2026 Earnings Transcript
01-06-2026
fool.com
Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
03-06-2026
yahoo.com
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
03-06-2026
yahoo.com
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
04-06-2026
yahoo.com
FMS Launches kinexus Digital Platform for Home Dialysis Care
05-06-2026
yahoo.com
FMS and Home Dialysis: How 5008X Could Reset Demand
08-06-2026
yahoo.com
Interwell Health Delivers Strong Quality Scores and Shared Savings in CMS Value-Based Kidney Care Model
10-06-2026
yahoo.com
What is the current price of FRESENIUS MEDICAL CARE-ADR (FMS:NYSE)?
The current price of FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) is $23.03.
FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) absolute price change since previous trading day?
The absolute price change of FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) since the previous trading day is $0.66.
FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) percentage price change since previous trading day?
The percentage price change of FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) since the previous trading day is 2.9504%.
What is the most recent average sentiment score for FRESENIUS MEDICAL CARE-ADR (FMS:NYSE)?
The most recent average sentiment score for FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) is 72 out of 100.
What is the most recent average sentiment for FRESENIUS MEDICAL CARE-ADR (FMS:NYSE)?
The most recent sentiment for FRESENIUS MEDICAL CARE-ADR (FMS:NYSE) is .
SEC-8K** Filing Available For FRESENIUS MEDICAL CARE-ADR (FMS:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.